Sonnet BioTherapeutics Launches Clinical Research for SON-1210
Preclinical studies indicate that SON-1210, an innovative bifunctional IL-12/IL-15 fusion protein that binds to albumin, shows potential for immunotherapy in treating solid tumors.
The Innovative Immuno Oncology Consortium (IIOC), with the support of the Sarcoma Oncology Center, is initiating a Phase 1/2a study of SON-1210 aimed at addressing pancreatic cancer, which currently has significant unmet medical needs.
Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company dedicated to developing targeted immunotherapeutics, has announced the establishment of a Master Clinical Collaboration Agreement with the Sarcoma Oncology Center. This agreement is crucial for advancing the development of SON-1210 in combination with chemotherapy for metastatic pancreatic cancer.
Goals of the Collaboration and Its Strategic Importance
Pankaj Mohan, Ph.D., the Founder and CEO of Sonnet, shared his excitement about the partnership, stating, “We are thrilled to collaborate with this esteemed organization to expand treatment options for patients in urgent need. Our goal is to gather essential data in this critical cancer area, which we believe will strengthen our data portfolio and help us manage our financial resources effectively.”
Insights from Experts on Pancreatic Cancer Treatment
Dr. Andrew Hendifar, an expert in developing new therapies for pancreatic cancer and neuroendocrine tumors, pointed out the increasing incidence of pancreatic cancer and the limited progress in treatments beyond standard chemotherapy. He noted, “Innovative immunotherapies like SON-1210 offer a significant opportunity to improve patient outcomes.”
Overview of the Clinical Study
As part of the collaboration, the IIOC, led by Dr. Sant Chawla at the Sarcoma Oncology Center, will design and conduct an investigator-initiated Phase 1/2a study to evaluate SON-1210 in conjunction with various chemotherapy agents, including liposomal irinotecan, 5-fluorouracil/leucovorin, and oxaliplatin (referred to as NALIRIFOX). NALIRIFOX is recognized by the FDA for treating both front-line and refractory metastatic pancreatic cancer, underscoring the importance of this study.
SON-1210's Innovative Mechanisms and Benefits
Dr. Chawla highlighted the significance of the collaboration, stating, “Tumors preferentially utilize albumin, which suggests that albumin-bound therapies like SON-1210 could greatly enhance both efficacy and safety through targeted action. This strategy builds on our understanding of tumor biology, especially in a context where immunotherapies are not yet approved for pancreatic cancer.”
Dr. John Cini, Chief Scientific Officer and Co-Founder of Sonnet, elaborated on the advantages of SON-1210. He emphasized its ability to improve tumor targeting and retention by four to five times compared to conventional cytokines, addressing a pressing unmet medical need in the treatment of pancreatic cancer.
Preclinical Safety and Efficacy Findings
Recently, the Company successfully completed two IND-enabling toxicology studies of SON-1210 in non-human primates, which yielded encouraging results with no significant toxicity observed. Notably, there was a temporary increase in interferon gamma (IFN-?) following administration, suggesting the immunotherapeutic potential of this candidate.
Overview of SON-1210
SON-1210 is a groundbreaking bifunctional immunotherapeutic candidate that combines IL-12 and IL-15 with an albumin-binding domain. Its design aims to effectively deliver these cytokines in tumor environments, thereby stimulating a strong immune response.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is a biotechnology company focused on oncology, dedicated to creating innovative biological drugs using its proprietary FHAB platform. This technology utilizes a human antibody fragment to transport therapeutic agents, ensuring targeted delivery to tumor tissues.
Frequently Asked Questions
1. What is SON-1210, and how does it work?
SON-1210 is a bifunctional immunotherapeutic drug that combines interleukins IL-12 and IL-15, aimed at enhancing immune responses in the treatment of various cancers, particularly pancreatic cancer.
2. What is the significance of the study on SON-1210?
The study seeks to evaluate the effectiveness of SON-1210 when used with chemotherapy, filling a crucial gap in treatment options for patients suffering from metastatic pancreatic cancer.
3. Who is conducting the clinical study of SON-1210?
The clinical study is led by the Innovative Immuno Oncology Consortium, under the direction of Dr. Sant Chawla at the Sarcoma Oncology Center.
4. What are the potential benefits of using SON-1210?
SON-1210 has the potential to improve treatment outcomes for pancreatic cancer patients by utilizing its unique mechanism that enhances cytokine targeting while minimizing toxicity compared to traditional therapies.
5. How does Sonnet BioTherapeutics approach drug development?
Sonnet BioTherapeutics employs its proprietary FHAB platform to innovate biologic drugs, focusing on enhancing their therapeutic efficacy and safety profiles through targeted delivery mechanisms.
